Financière de Tubize S.A.
TUB
주식 순위
#2219
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
주가
$203.04
시가총액
$9.04B
변동 (1일)
-7.47%
변동 (1년)
-25.36%
국가
BE
거래 Financière de Tubize S.A. (TUB)
카테고리
Healthcare
Financière de Tubize S.A. (TUB)의 수익
Jun 2026 기준 수익 TTM: $116.73M
Financière de Tubize S.A.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $116.73M입니다. 2023년에 회사는 $97.45M의 수익을 올렸으며 이는 2022년의 수익 $91.36M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Financière de Tubize S.A.의 수익 기록 (2003 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $116.73M | 24.50% |
| 2024 | $93.76M | -3.79% |
| 2023 | $97.45M | 6.66% |
| 2022 | $91.36M | -3.90% |
| 2021 | $95.07M | -70.04% |
| 2020 | $317.28M | -0.32% |
| 2019 | $318.31M | -2.86% |
| 2018 | $327.69M | 2.60% |
| 2017 | $319.38M | 68.35% |
| 2016 | $189.71M | -16.83% |
| 2015 | $228.09M | 209.22% |
| 2014 | $73.76M | -15.46% |
| 2013 | $87.25M | -16.53% |
| 2012 | $104.53M | 15.02% |
| 2011 | $90.88M | 221.98% |
| 2010 | $28.23M | -87.95% |
| 2009 | $234.25M | -15,867.73% |
| 2008 | $-1.49M | -102.49% |
| 2007 | $59.74M | -90.49% |
| 2006 | $628.45M | 78.57% |
| 2005 | $351.93M | 105.84% |
| 2004 | $170.97M | 14.90% |
| 2003 | $148.80M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | 4,418.76% |
US
|
|
| $-3.09B | -2,744.49% |
US
|
|
| $-4.02B | -3,540.48% |
AU
|
|
| $1.95B | 1,571.03% |
NL
|
|
| - | - |
CH
|
